Metaraminol
- Generic Name
- Metaraminol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13NO2
- CAS Number
- 54-49-9
- Unique Ingredient Identifier
- 818U2PZ2EH
- Background
An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine. It has been used primarily as a vasoconstrictor in the treatment of hypotension.
- Indication
For the treatment and prevention of hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage
- Associated Conditions
- -
- Associated Therapies
- -
Effect of Three Weight-adjusted Vasopressors for Elective Cesarean Delivery
- Conditions
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Xuzhou Medical University
- Target Recruit Count
- 78
- Registration Number
- NCT04991662
- Locations
- 🇨🇳
Department of Anesthesiology and Operating Room, Affiliated Hospital of Peking University People's Hospital, Peking, Beijing, China
Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation
- Conditions
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02245191
- Locations
- 🇧🇷
University of São Paulo, São Paulo, Brazil
Maternal and Neonatal Outcomes of the Use of Vasopressors to Treat Hypotension During Spinal Anesthesia for Cesarean
- Conditions
- Locations
- 🇧🇷
Instituto de Medicina Integral Professor Fernando Figueira, Recife, Pernambuco, Brazil
Up-Down Determination of the ED90 of Metaraminol to Treat Hypotension During Cesarean Section
- Conditions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2010-10-01
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 48
- Registration Number
- NCT01108874
- Locations
- 🇧🇷
Hospital São Paulo, São Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.